{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:01:33Z","timestamp":1790650893103,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.critrevonc.2025.105049","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T15:20:34Z","timestamp":1763911234000},"page":"105049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prognostic value of CD49d in CLL: Systematic review and meta-analysis"],"prefix":"10.1016","volume":"217","author":[{"given":"Piotr","family":"Liman\u00f3wka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Szczuraszyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Moszy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"S\u0119dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.105049_bib1","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1158\/1078-0432.CCR-22-3217","article-title":"CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy","volume":"29","author":"Alsadhan","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105049_bib2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"A meta-analysis of individual patient data","volume":"17","author":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI)","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bjh.13788","article-title":"CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated status","volume":"172","author":"Baumann","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/ijms19020485","article-title":"Integrins in T cell physiology","volume":"19","author":"Bertoni","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.105049_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70008","article-title":"Molecular profiling identifies CD49d and CD79b as predictive markers for acquired acalabrutinib resistance in patients with chronic lymphocytic leukemia","volume":"43","author":"Bibikova","year":"2025","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib6","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1080\/10428194.2024.2394583","article-title":"Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function","volume":"65","author":"Bohn","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2025.105049_bib7","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.3390\/cancers16223744","article-title":"Beta-2-microglobulin maintains overall survival prediction in binet A stage chronic lymphocytic leukemia patients with compromised kidney function in both treatment eras of chemoimmunotherapy and targeted agents","volume":"16","author":"Bohn","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.105049_bib8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00277-013-1967-y","article-title":"The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia","volume":"93","author":"Brachtl","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","article-title":"CD49d Is the strongest flow cytometry\u2013based predictor of overall survival in chronic lymphocytic leukemia","volume":"32","author":"Bulian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib10","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/leu.2016.88","article-title":"CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia","volume":"30","author":"Dal Bo","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2025.105049_bib11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/j.seminhematol.2014.05.002","article-title":"Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d","volume":"51","author":"Dal Bo","year":"2014","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/10428190903350421","article-title":"Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia","volume":"51","author":"Del Poeta","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2025.105049_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107541","article-title":"Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT)","volume":"143","author":"Galieni","year":"2024","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2025.105049_bib14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2007-05-092486","article-title":"Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia","volume":"111","author":"Gattei","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105049_bib15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/ejh.13833","article-title":"Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia","volume":"109","author":"Giudice","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib16","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1182\/bloodadvances.2022009040","article-title":"Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL","volume":"7","author":"Griffin","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.105049_bib17","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib18","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bcmd.2015.05.010","article-title":"CD49d and CD26 are independent prognostic markers for disease progression in patients with chronic lymphocytic leukemia","volume":"55","author":"Ibrahem","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.critrevonc.2025.105049_bib20","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3390\/cancers15051583","article-title":"Emerging Therapies in CLL in the Era of Precision Medicine","volume":"15","author":"Iyer","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.105049_bib21","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0140-6736(24)00595-6","article-title":"Chronic lymphocytic leukaemia","volume":"404","author":"Jain","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.105049_bib22","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1002\/ajh.26457","article-title":"Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis","volume":"97","author":"Jelloul","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100930","article-title":"CLL update 2022: A continuing evolution in care","volume":"54","author":"Kay","year":"2022","journal-title":"Blood Rev."},{"key":"10.1016\/j.critrevonc.2025.105049_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000533610","article-title":"Chronic lymphocytic leukemia: disease biology","volume":"147","author":"Koehrer","year":"2023","journal-title":"Acta Haematol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib25","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.2023022564","article-title":"Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies","volume":"143","author":"Langerbeins","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105049_bib26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cca.2018.04.026","article-title":"ZAP-70 in chronic lymphocytic leukemia: a meta-analysis","volume":"483","author":"Liu","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.critrevonc.2025.105049_bib27","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.leukres.2010.10.022","article-title":"CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL","volume":"35","author":"Majid","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2025.105049_bib28","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1186\/s12885-022-10223-0","article-title":"Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors","volume":"22","author":"Mkhwanazi","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.105049_bib29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.clim.2009.02.004","article-title":"High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia","volume":"131","author":"N\u00fcckel","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.critrevonc.2025.105049_bib31","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105049_bib32","article-title":"Targeting integrin pathways: mechanisms and advances in therapy","volume":"8","author":"Pang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2025.105049_bib33","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/cells11142235","article-title":"Integrin signaling shaping BTK-inhibitor resistance","volume":"11","author":"Polcik","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2025.105049_bib34","unstructured":"R Core Team, 2024. R: A language and environment for statistical computing. R Foundation for Statistical Computing."},{"key":"10.1016\/j.critrevonc.2025.105049_bib35","doi-asserted-by":"crossref","first-page":"k4597","DOI":"10.1136\/bmj.k4597","article-title":"A guide to systematic review and meta-analysis of prognostic factor studies","author":"Riley","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.105049_bib36","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3324\/haematol.13103","article-title":"CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia","volume":"93","author":"Rossi","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2025.105049_bib37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","article-title":"Chronic lymphocytic leukaemia","volume":"104","author":"Scarf\u00f2","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib38","unstructured":"Schwarzer, G., 2025. meta: General Package for Meta-Analysis."},{"key":"10.1016\/j.critrevonc.2025.105049_bib39","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V93.2.624","article-title":"Reduced expression of adhesion molecules and cell signaling receptors by chronic lymphocytic leukemia cells with 11q deletion","volume":"93","author":"Sembries","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105049_bib40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1445-5994.2010.02294.x","article-title":"Clinical utility of molecular and flow cytometric markers in chronic lymphocytic leukaemia","volume":"42","author":"Sulda","year":"2012","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.critrevonc.2025.105049_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.critrevonc.2025.105049_bib43","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1084\/jem.20171288","article-title":"Functional and clinical relevance of VLA-4 (CD49d\/CD29) in ibrutinib-treated chronic lymphocytic leukemia","volume":"215","author":"Tissino","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2025.105049_bib44","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41375-024-02376-7","article-title":"The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands","volume":"38","author":"Tissino","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2025.105049_bib45","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1182\/blood.2019003179","article-title":"CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression","volume":"135","author":"Tissino","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105049_bib46","doi-asserted-by":"crossref","DOI":"10.5505\/tjh.2012.62687","article-title":"The prognostic value of CD49d expression in Turkish patients with chronic lymphocytic leukemia","author":"Uzay","year":"2012","journal-title":"Turk. J. Hematol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jrsm.1319","article-title":"Methods to calculate uncertainty in the estimated overall effect size from a random-effects meta-analysis","volume":"10","author":"Veroniki","year":"2019","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.critrevonc.2025.105049_bib48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41435-024-00258-7","article-title":"CXCR4 overexpression in chronic lymphocytic leukemia associates with poorer prognosis: A prospective, single-center, observational study","volume":"25","author":"Xue","year":"2024","journal-title":"Genes Immun."},{"key":"10.1016\/j.critrevonc.2025.105049_bib49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12938-021-00973-6","article-title":"The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019","volume":"21","author":"Yao","year":"2022","journal-title":"Biomed. Eng. OnLine"},{"key":"10.1016\/j.critrevonc.2025.105049_bib50","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/jcp.20570","article-title":"A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia","volume":"207","author":"Zucchetto","year":"2006","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.critrevonc.2025.105049_bib51","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1182\/blood-2013-06-507335","article-title":"CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism","volume":"122","author":"Zucchetto","year":"2013","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T19:42:00Z","timestamp":1768333320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":51,"alternative-id":["S1040842825004378"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105049","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value of CD49d in CLL: Systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105049"}}